

**Practical Symposium – Radiopharmacy and oncology pharmacy
from 16:00 - 17:30 – 1st floor – Hall X3**



Michal Budinsky, Czech Republic



Maria Cecilia Giron, Italy



Natalia Dengina, Russian Federation

Radiation oncology, which has traveled a distance of about 130 years, has reached incredible dimensions in terms of technological developments and treatment effectiveness. Currently, more than 50% of cancer patients receive radiation therapy at various stages of treatment, primarily using external beam radiation. Pharmacists' involvement in the radiopharmaceutical field can vary widely from country to country, depending on national laws and the type of facility supplying the radiopharmaceuticals. Starting from the university education period, radiopharmacy education, post-graduate specialist radiopharmacy training and personal develop-

ment opportunities can increase the interest of pharmacy personnel in this branch of pharmacy. In the nuclear medicine department, pharmacy personnel are represented by radiopharmacists and radiopharmaceutical laboratory technicians. The presence of a university-trained radiopharmacist is essential as a guarantee of good radiopharmaceutical practice (GRP). Collaboration between radiopharmacists and radiopharmaceutical laboratory technicians enables more difficult radiopharmaceutical technologies to be managed in terms of quality and safety. Safe radiotherapy practice requires a multidisci-

plinary team of nuclear medicine doctors, radiopharmacists, physicists and nurses who specialize in ensuring patient safety. In the last decade, innovative targeted development radionuclide strategies have provided effective therapeutic modalities against cancer. Also a survey made specifically in Russia to understand what is the role of radiopharmacists in the country and the interaction between oncologists (radiation, medical) and clinical pharmacologists during conservative treatment of cancer patients and how close it is will be presented on the session.



Organ Concert on the 30th June 2022: St. Michaelis Church

Workshops:

Quick info

14:00-15:30 – 1st floor – Hall X2

**Practical stability studies for anticancer drugs:
How to perform? How to find relevant information?**

**Jean Vigneron and Elise d'Huart, France
& Robert Terkola, Austria**

14:00-15:30 – 3rd floor – Hall Z

Car-T cells - Role of Pharmacy in Car-Tcells management

**Isabelle Madelaine Chambrin, France, Vito Ladisa, Italy
& Julia Zuenkova, Russian Federation**



European Conference of Oncology Pharmacy - Friday 1st July 2022

Dear participants,

I would like to wish you all a very inspirational and productive exchange at this 5th European Conference of Oncology Pharmacy in Hamburg. After more than two years of living with COVID, public health measures and social distancing, I am happy to see that you can once again get together in person, of course whilst maintaining a COVID safe conference. We are still living in pandemic times and caution and vigilance is still very much required.

These past two years have been very challenging for the health care sector overall. Europe's cancer patients and oncology sector in particular have been greatly affected. Millions of cancer patients have not been able to access screening, which will lead to late diagnosis affecting cancer outcomes over the next two years. Only together can we rise to this challenge, bridge the care gap that we have witnessed and ensure effective cancer prevention, treatment and care accessible to all.

To do so, collaboration and coordination are vital. Between medical teams delivering a patient's care. Between researchers developing innovative new approaches. Between hospitals and health systems sharing expertise and understanding. Patient groups, industry, policy makers, and health care professionals – we all have a role to play. But the crucial point is that we are stronger, more effective and more resilient together.

The members of the European Society of Oncology Pharmacy are vital cornerstones for our joint work and for the quality of the work of the EU's oncology sector.



I am very much looking forward to presenting the new EU recommendation on cancer screening after the Summer. And I am very much looking forward to working closely with you all as we continue to turn the commitments taken under Europe's Beating Cancer Plan into action. I wish you an excellent conference and sincerely hope I can be with you in person next time.

Yours

Stella Kyriakides,
Commissioner

And with Europe's Beating Cancer Plan, the first EU Cancer Plan, we have unprecedented possibilities to work together to improve the situation of our cancer patients and their families.

We have already made important progress, with 16 major actions launched last year, including a new Knowledge Centre, training for cancer professionals, support on vaccination against HPV, the start of the creation of an EU Network of National Comprehensive Cancer Centres and the work to establish the first ever EU Code of Conduct to ensure fair access to financial services for persons with a history of cancer. We have had a busy and productive first year, and will continue in this spirit for the years to come.

**Take part in our [mini](#)
Congress survey ECOP5:**



until today evening!

© Copyright:

ESOP
Veritaskai 6
21079 Hamburg
Germany
Editor: Kleio Bourika,
Eda Gedikoglu,
Carolin Meier, Anja Blank

**Round table –
Multicenter real world data studies,
which impact can they generate?
from 12:00 - 13:00 – 1st floor – Hall X1**

Nowadays, immunotherapy is an exploding way to treat cancer. The terms immunotherapy includes several strategies. Immune checkpoint inhibitors, are drugs that block immune checkpoints which are a normal part of the immune system controlling the immune response. Checkpoint proteins, such as PD-L1 on tumour cells and PD-1 on T cells, help keep immune responses in check. By blocking them, these drugs, such as nivolumab, pembrolizumab or durvalumab, stimulate immune cells against cancer cells.



Cristina Ibanez Collado, Spain

Monoclonal antibodies, such as trastuzumab, rituximab or cetuximab, are designed to bind, by their Fab fragment, to cancer cells exhibiting the corresponding specific antigen or to block growing factors. Treatment vaccines, work by boosting immune system response to cancer cells. Cancer immunotherapy has significantly improved the prognosis of cancer patients, but the majority experience limited benefit, evidencing the need for new therapeutic approaches. Resistance to cancer immunotherapy from factors causing limited therapy can be explained by tumor cell intrinsic factors and obstacles in the tumor microenvironment. There are approaches to overcoming resistance, focusing on emerging therapy modalities.



Marko Skelin, Croatia

**Clinical Symposium – Immunotherapy
from 16:00 - 17:30 – 3rd floor – Hall Z**



Heinz Läubli, Switzerland



Joao Goncalves, Portugal



Alain Astier, France

Nowadays, immunotherapy is an exploding way to treat cancer. The terms immunotherapy includes several strategies. Immune checkpoint inhibitors, are drugs that block immune checkpoints which are a normal part of the immune system controlling the immune response. Checkpoint proteins, such as PD-L1 on tumour cells and PD-1 on T cells, help keep immune responses in check. By blocking them, these drugs, such as nivolumab, pembrolizumab or durvalumab, stimulate immune cells against cancer cells. Monoclonal antibodies, such as trastuzumab, rituximab or cetuximab, are designed to bind, by their Fab fragment,

to cancer cells exhibiting the corresponding specific antigen or to block growing factors. Treatment vaccines, work by boosting immune system response to cancer cells. Cancer immunotherapy has significantly improved the prognosis of cancer patients, but the majority experience limited benefit, evidencing the need for new therapeutic approaches. Resistance to cancer immunotherapy from factors causing limited therapy can be explained by tumor cell intrinsic factors and obstacles in the tumor microenvironment. There are approaches to overcoming resistance, focusing on emerging therapy modalities.



Exhibition – 2nd floor – Hall Y

Today you can visit the Exhibition from 8:30-17:00.

41 booth with 45 companies

On Saturday, 2nd July 2022 the Exhibition opens from 07:45-14:30.



**Joint ESOP - SIOPE Symposium – Extemporaneous preparations for children, back to the future
from 11:00-12:30 – 1st floor – Hall X3**




Sherif Kamal, Egypt

Essential anticancer medicines are a principal component of evidencebased best practice in paediatric cancer care, generating an 80% disease free survival at 5 years in malignancies affecting children and adolescents <18 years of age. Most medicines used for childhood cancers are off-patent, available as generics, and prescribed off-label in the paediatric population. In the study, conducted as part of the EU Joint Action on Rare Cancers (JARC) project, health professionals reported that 27% of the oral essential medicines on the survey list were never available in an age-appropriate formulation for administration in young patients. Parents overwhelmingly confirmed



Svetlana Buraja, Latvia

this finding, reporting complex manual format adjustments and the distress experienced in the process. Extemporaneous compounding in hospitals and community pharmacies is pivotal since it enables the preparation of age-appropriate dosage forms when suitable authorised medicines are not available. Since many medicines are not licensed for use in paediatric populations, the manufacturer does not ordinarily produce age-appropriate dosage forms for the market. There are also circumstances where the medicines are not available from commercial suppliers: shortages of medicines, discontinued medicines, special combinations or orphan medicines.



Gilles Vassal, France

Therefore, SIOPE and ESOP made a recommendations with the aim to set a European standard for developing paediatric specific extemporaneous formulations to promote appropriate administration of medicines for children and reach a meaningful therapeutic benefit to those patients over existing therapies.

Quick info

**Poster Viewing: 08:30-17:00
3rd floor – Foyer Z**

**Exhibition: 08:30-17:00
2nd floor – Hall Y**

**Award Session – Advances in Surgical Oncology
from 12:30-13:00 – 1st floor – Hall X3**

Surgical Oncology (SO) has been evolving during the years to become the n.1 weapon against solid tumours. However, times are rapidly changing. The new scenario we are facing demands deep understanding of the whole armamentarium presently available to the oncological community and the ones we will soon progress to. There is a strong public demand, and we need to keep our patients reassured that we are on the cutting edge of new scientific developments. To keep up to speed SO needs to engage into research, develop state-of-the-art studies, particularly population based IV phase trials, where realtime data capture will be assisted by AI. Numerous surgical techniques have been developed and implemented. A great amount of effort



Riccardo Audisio, UK

has recently been put into homogenising education in SO, by promoting accredited specialist care and certifying trained surgeons.



The 2021 Award is presented today to Riccardo Audisio. Due to his tireless support in multi-professional committees and practical participation in ESOP activities through publications and lectures, he has rendered outstanding services to the ESOP. His efforts for scientific specialisation in surgical oncology inspire the same efforts in our organisation.